Equities

ICeram SA

ALICR:PAR

ICeram SA

Actions
Health CareMedical Equipment and Services
  • Price (EUR)1.00
  • Today's Change-0.05 / -4.76%
  • Shares traded354.00
  • 1 Year change-88.89%
  • Beta1.0218
Data delayed at least 15 minutes, as of Apr 26 2024 14:45 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

I.Ceram SA is a France-based company engaged in design and manufacture of joint implants. It offers implants for various body parts, produced of metal, polymer and ceramic. The Company has own laboratory and researchers developing a range of bone fillers.

  • Revenue in EUR (TTM)1.10m
  • Net income in EUR-903.08k
  • Incorporated2005
  • Employees25.00
  • Location
    ICeram SA1 rue Columbia - Parc d'EsterLIMOGES 87280FranceFRA
  • Phone+33 555691212
  • Fax+33 555350650
  • Websitehttps://www.iceram.fr/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ICeram SA1.10m-903.08k295.46k25.00--0.16--0.2681-3.10-3.103.786.250.21410.02692.9945,912.50-17.55-23.88-24.43-31.5394.8774.47-81.96-108.630.8712-30.290.4983---9.93-0.9989-21.27------
Audientes A/S169.76k-1.80m515.42k11.00k--0.8184--3.04-0.3407-0.34070.02850.06770.0618-0.05370.6894115.09-65.40-47.21-155.90-64.67117.14---1,058.85-4,172.600.1708-6.570.0123--1,502.53--44.98------
Spineway SA10.52m-6.51m712.18k54.00--0.0032--0.0677-2,095.06-2,095.06147.09266.450.38950.6344.57194,796.30-24.11-28.83-29.65-37.2674.8980.13-61.89-91.901.09-48.930.1206--41.5410.06-107.52------
Perpetua Medical AB (publ)850.61k-1.56m843.53k----0.7453--0.9917-0.5927-0.59270.23220.12180.63786.603.78---117.31-83.52-164.97-102.1958.8563.46-183.94-250.302.14--0.0068---1.7657.204.63--8.89--
Qlife Holding AB20.89k-13.69m877.43k--------42.01-0.2636-0.26360.0003-0.02230.00211.540.2847---138.07---256.73---4,761.48---65,556.15--0.1683-19.45-----98.64---71.74------
Medfield Diagnostics AB61.04k-1.29m1.46m----0.2312--23.93-0.2513-0.25130.0120.92980.0093-1.880.5942---19.55-14.34-20.52-15.38765.78547.85-2,106.17-826.132.61-12.28-----70.29---79.42--3.75--
Data as of Apr 26 2024. Currency figures normalised to ICeram SA's reporting currency: Euro EUR

Institutional shareholders

2.37%Per cent of shares held by top holders
HolderShares% Held
OFI Invest Asset Management SAas of 29 Feb 20247.00k2.37%
Data from 27 Mar 2024 - 27 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.